TABLE 1.

Baseline clinical characteristics of patients with IDH‐mutant astrocytoma.

	WHO 2–3 (n = 27)	WHO 4 (n = 33)	p Value
General features
Sex
Male	15 (55.56%)	27 (81.82%)	0.027*
Female	12 (44.44%)	6 (18.18%)
Age (Mean ± SD, range)	40.85 ± 10.38, 21–62	44.12 ± 12.78, 23–74	0.431
BMI (Mean ± SD)	24.95 ± 3.14	23.82 ± 2.48	0.262
KPS (Median/range)	90 (10–100)	90 (10–100)	0.847
CCI (Median/range)	1 (0–3)	1 (0–7)	0.978
Detection‐to‐neurosurgery time/week (Median/range)	5 (1–676)	6.5 (1–832)	0.370
Recurrence	2 (7.41%)	12 (36.36%)	0.006*
Neurological symptoms
Headache	13 (48.15%)	17 (51.52%)	0.467
Dizzy	6 (22.22%)	6 (18.18%)
Nausea and vomit	4 (14.81%)	9 (27.27%)
Limb weakness	6 (22.22%)	8 (24.24%)
Sensory deficit	3 (11.11%)	5 (15.15%)
Vision and visual field disorders	2 (7.41%)	1 (3.03%)
Urinary and fecal incontinence	1 (3.70%)	1 (3.03%)
Seizure	8 (29.63%)	15 (45.45%)
Mental disorder and personality change	3 (11.11%)	1 (3.03%)
Treatment
Neurosurgery
Gross total resection	15 (55.56%)	19 (57.58%)	0.823
Subtotal resection	3 (11.11%)	3 (9.09%)
Partial resection	4 (14.81%)	6 (18.18%)
Biopsy	2 (7.41%)	5 (15.15%)
NA	3 (11.11%)	0 (0.00%)
Adjuvant therapy
STUPP	9 (33.33%)	15 (45.45%)	0.088
Neurosurgery	2 (7.41%)	2 (6.06%)
Radiotherapy	1 (3.70%)	2 (6.06%)
Temozolomide	3 (11.11%)	3 (9.09%)
Anti‐angiogenic therapy	2 (7.41%)	3 (9.09%)
Other	1 (3.70%)	4 (12.12%)
NA	6 (22.22%)	9 (27.27%)

Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; KPS, Karnofsky performance status; NA, loss of data.

Bold values means p value < 0.05